Scarica l'app Stockscreener
8.90
4.09%
-0.38
Dopo l'orario di chiusura:
8.96
0.06
+0.67%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie
Cyclacel Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Cyclacel Pharmaceuticals Implements Reverse Stock Split in July - TipRanks
Cyclacel reports Q2 financials, declares $0.15/share dividend. - AInvest
Cyclacel Pharmaceuticals, Inc. Reports Second Quarter 2025 Financial Results and Business Developments - Quiver Quantitative
Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Pharmaceuticals Slashes Losses to $1.3M, Plans Strategic Malaysian Expansion - Stock Titan
Cyclacel Pharmaceuticals files audited Q1 financials to support S-3 eligibility - Investing.com Canada
Cyclacel Pharmaceuticals Announces $1 Million Private Placement Offering of Convertible Preferred Stock - The Globe and Mail
What makes Cyclacel Pharmaceuticals Inc. stock price move sharplyFree Momentum Stock List - thegnnews.com
Cyclacel Pharmaceuticals Announces That Kenneth M. Ferguson, Ph.D. Was Elected to Its Board of Directors - The Globe and Mail
Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS - MSN
Cyclacel (CYCC) Stock Sees Strong Pre-Market Performance After New Study Results - 富途牛牛
Cyclacel Pharmaceuticals Inc. (CYCC) Soars 34.86% on Encouraging Preclinical Results - AInvest
Cyclacel Pharmaceuticals Stock Up 34.6% In Massive After-Hours Rally - Benzinga
Major Shareholder Cashes Out on Cyclacel Pharmaceuticals Stock! - TipRanks
CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB - The Manila Times
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Breakthrough: Novel Drug Plogosertib Effectively Targets Aggressive Biliary Cancer, Study Reveals Key Biomarker - Stock Titan
WeightWatchers Reschedules Second Quarter 2025 Earnings Release and Conference Call to Finalize Fresh Start Accounting Adoption in Connection with Emergence - The Globe and Mail
What are the technical indicators suggesting about Cyclacel Pharmaceuticals Inc.Tap into rapid wealth building techniques - Jammu Links News
What are analysts’ price targets for Cyclacel Pharmaceuticals Inc. in the next 12 monthsInvest in stocks with strong fundamentals - Jammu Links News
Is Cyclacel Pharmaceuticals Inc. stock overvalued or undervaluedAchieve breakthrough gains with expert advice - Jammu Links News
What are Cyclacel Pharmaceuticals Inc. company’s key revenue driversDynamic investment opportunities - Jammu Links News
How volatile is Cyclacel Pharmaceuticals Inc. stock compared to the marketAchieve breakthrough gains with smart trades - Jammu Links News
How does Cyclacel Pharmaceuticals Inc. compare to its industry peersUnlock powerful trading tools for investors - Jammu Links News
What is the dividend policy of Cyclacel Pharmaceuticals Inc. stockInvest smarter with actionable stock recommendations - Jammu Links News
What institutional investors are buying Cyclacel Pharmaceuticals Inc. stockHigh-yield investments - Jammu Links News
What drives Cyclacel Pharmaceuticals Inc. stock priceCapitalize on stocks with high profit margins - Jammu Links News
Should I hold or sell Cyclacel Pharmaceuticals Inc. stock in 2025Maximize returns with timely market signals - Jammu Links News
When is Cyclacel Pharmaceuticals Inc. stock expected to show significant growthAchieve breakthrough profits with smart strategies - Jammu Links News
What is the risk reward ratio of investing in Cyclacel Pharmaceuticals Inc. stockGet real-time alerts on top stocks - Jammu Links News
Cyclacel Pharmaceuticals Inc. Stock Analysis and ForecastAchieve consistent profits with smart trading - Jammu Links News
What are the latest earnings results for Cyclacel Pharmaceuticals Inc.Unprecedented growth rates - Jammu Links News
What is Cyclacel Pharmaceuticals Inc. company’s growth strategyGame-changing returns - Jammu Links News
Published on: 2025-08-03 02:26:26 - Jammu Links News
3 Artificial Intelligence (AI) Stocks That Could Make You a Millionaire - The Globe and Mail
MELI Set to Report Q2 earnings: Time to Hold or Fold the Stock? - The Globe and Mail
Is it the right time to buy Cyclacel Pharmaceuticals Inc. stockStock Strategy Recommendation For Every Investor - jammulinksnews.com
IBM Report: Canadians' Data Security Under Increased Threat, While Breach Costs Surge - The Globe and Mail
Using Python tools to backtest Cyclacel Pharmaceuticals Inc. strategiesMomentum Trading Guide with Safety Limits - Newser
What Technical Tools Say About Cyclacel Pharmaceuticals Inc. RecoveryFast Entry High Potential Stock Alerts Triggered - metal.it
Verisign’s Earnings Call: Strong Growth Amid Caution - The Globe and Mail
Celestica Beats Q2 Earnings Estimates on Solid Top-Line Growth - The Globe and Mail
How high can Cyclacel Pharmaceuticals Inc. stock goAI Trade Signal Forecast with Chart Logic - Newser
Custom strategy builders for tracking Cyclacel Pharmaceuticals Inc.Free Daily Momentum Screener With Alerts - Newser
Cyclacel Pharmaceuticals Inc. recovery potential after sell offWeekly Gain Forecast with Momentum Indicators - Newser
Full technical analysis of Cyclacel Pharmaceuticals Inc. stockProven Trading System with Consistent Gains - Newser
What the charts say about Cyclacel Pharmaceuticals Inc. todayConservative Asset Allocation Risk Analysis - Newser
Why Cyclacel Pharmaceuticals Inc. stock attracts strong analyst attentionReal-Time Entry Signals for Top Stocks - Newser
Is Cyclacel Pharmaceuticals Inc. Starting a New UptrendSector Based Breakout Stock Forecast Issued - metal.it
Cyclacel Pharmaceuticals Amends Series F Stock Limitations - TipRanks
How strong is Cyclacel Pharmaceuticals Inc. company’s balance sheetExpert Picks Tips With High Returns - Jammu Links News
Does Cyclacel Pharmaceuticals Inc. stock perform well during market downturnsHigh-profit stock alerts - Jammu Links News
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):